Antonie van Leeuwenhoek

, Volume 110, Issue 9, pp 1219–1226 | Cite as

Synergy between azoles and 1,4-dihydropyridine derivative as an option to control fungal infections

  • Zuzana Ježíková
  • Tomáš Pagáč
  • Barbora Pfeiferová
  • Helena Bujdáková
  • Stanislava Dižová
  • Iva Jančíková
  • Dana Gášková
  • Petra Olejníková
Original Paper

Abstract

With emerging fungal infections and developing resistance, there is a need for understanding the mechanisms of resistance as well as its clinical impact while planning the treatment strategies. Several approaches could be taken to overcome the problems arising from the management of fungal diseases. Besides the discovery of novel effective agents, one realistic alternative is to enhance the activity of existing agents. This strategy could be achieved by combining existing antifungal agents with other bioactive substances with known activity profiles (combination therapy). Azole antifungals are the most frequently used class of substances used to treat fungal infections. Fluconazole is often the first choice for antifungal treatment. The aim of this work was to study potential synergy between azoles and 1,4-dihydropyridine-2,3,5-tricarboxylate (termed derivative H) in order to control fungal infections. This article points out the synergy between azoles and newly synthesized derivative H in order to fight fungal infections. Experiments confirmed the role of derivative H as substrate/inhibitor of fungal transporter Cdr1p relating to increased sensitivity to fluconazole. These findings, plus decreased expression of ERG11, are responsible for the synergistic effect.

Keywords

ABC transporter Antifungal agents Efflux Fungal infection Synergy 

References

  1. Bowyer P, Moore CB, Rautemaa R, Denning DW, Richardson MD (2011) Azole antifungal resistance today: focus on Aspergillus. Curr Infect Dis Rep 13:485–491CrossRefPubMedGoogle Scholar
  2. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC (2012) Hidden killers: human fungal infections. Sci Transl Med 4:165rv13Google Scholar
  3. Chudik L, Marchalín Š, Daïch A, Decroix B (2000) New synthesis of the calcium antagonist Nilvadipine. Res Adv Synth Org Chem 1:1–7Google Scholar
  4. Clinical and Laboratory Standards Institute (CLSI) (1996) Reference method for broth dilution antifungal susceptibility testing yeast; approved standard. VA Medical Center, Tucson. NCCLS document M27-A 17Google Scholar
  5. Denning DW, Hope WW (2010) Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 18:195–204CrossRefPubMedGoogle Scholar
  6. Fonzi WA, Irwin MY (1993) Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717–728PubMedPubMedCentralGoogle Scholar
  7. Gášková D, Plášek J, Zahumenský J, Benešová I, Buriánková Ľ, Sigler K (2013) Alcohols are inhibitors of Saccharomyces cerevisiae multidrug-resistance pumps Pdr5p and Snq2p. FEMS Yeast Res 13:782–795CrossRefPubMedGoogle Scholar
  8. Hendrych T, Kodedová M, Sigler K, Gášková D (2009) Characterization of the kinetics and mechanisms of inhibition of drugs interacting with the S. cerevisiae multidrug resistance pumps Pdr5p and Snq2p. BBA-Biomembr 1788:717–723CrossRefGoogle Scholar
  9. Jia W, Zhang H, Li C, Li G, Liu X, Wei J (2016) The calcineurin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms. BMC Microbiol 16:1–10CrossRefGoogle Scholar
  10. Maschmeyer G (2006) The changing epidemiology of invasive fungal infections: new threats. Int J Anitimicrob Agents 27:3–6CrossRefGoogle Scholar
  11. Miceli MH, Lee SA (2011) Emerging moulds: epidemiological trends and antifungal resistance. Mycoses 54:666–678CrossRefGoogle Scholar
  12. Nailis H, Kucharíková S, Řičicová M, Van Dijck P, Deforce D, Nelis H, Coenye T (2010) Real-time PCR expression profiling of genes encoding potential virulence factors in Candida albicans biofilms: identification of model-dependent and -independent gene expression. BMC Microbiol 10:1–11CrossRefGoogle Scholar
  13. Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh TJ (2000) Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. J Clin Microbiol 38:1563–1568PubMedPubMedCentralGoogle Scholar
  14. Pfaller MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36:1–53CrossRefPubMedGoogle Scholar
  15. Rodloff AC, Koch D, Schaumann R (2011) Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res 16:187–195CrossRefPubMedPubMedCentralGoogle Scholar
  16. Ruhnke M (2014) Antifungal stewardship in invasive Candida infections. Clin Microbiol Infect 20:11–18CrossRefPubMedGoogle Scholar
  17. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod J, Bille J (1995) Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39:2378–2386CrossRefPubMedPubMedCentralGoogle Scholar
  18. Sanglard D, Ischer F, Monod M, Bille J (1996) Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 40:2300–2305PubMedPubMedCentralGoogle Scholar
  19. Sanglard D, Ischer F, Monod M, Bille J (1997) Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143:405–416CrossRefPubMedGoogle Scholar
  20. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G (2005) Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 49:668–679CrossRefPubMedPubMedCentralGoogle Scholar
  21. Szczepaniak J, Lukaszewicz M, Krasowska A (2015) Detection of inhibitors of Candida albicans Cdr transporters using a diS-C3(3) fluorescence. Front Microbiol 6:1–6Google Scholar
  22. Yu LH, Wei X, Ma M, Chen XJ, Xu SB (2012) Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm. Antimicrob Agents Chemother 56:770–775CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Institute of Biochemistry and Microbiology, Faculty of Chemical and Food TechnologySlovak University of Technology in BratislavaBratislavaSlovakia
  2. 2.Department of Microbiology and Virology, Faculty of Natural SciencesComenius UniversityBratislava 4Slovakia
  3. 3.Institute of Physics, Faculty of Mathematics and PhysicsCharles UniversityPraha 2Czech Republic

Personalised recommendations